Human EGFR Monoclonal Antibody, Endotoxin 0.05 EU/mg (YR0098)

Basic Information

Clone	Nimotuzumab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<0.05EU/mg (<0.00005EU/μg) Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Immunogen Information

Isotype	Human IgG1 kappa
Immunogen	Human EGFR
RecommendedIsotype Control(s)	In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer	1×PBS pH 7.0

* For research use only. Not for therapeutic or diagnostic purposes.